AAPL346.47-1.76 (-0.50%) ▼|ABBV286.27+1.08 (+0.38%) ▲|ABT103.39+0.88 (+0.85%) ▲|ACN246.85-11.89 (-4.60%) ▼|ADBE265.46-5.09 (-1.88%) ▼|AMAT379.68+4.10 (+1.09%) ▲|AMD517.55+9.62 (+1.89%) ▲|AMGN440.79-6.50 (-1.45%) ▼|AMT188.31+6.74 (+3.71%) ▲|AMZN248.72-1.66 (-0.66%) ▼|AVGO324.44+1.20 (+0.37%) ▲|AXP313.19-11.99 (-3.69%) ▼|BA188.39+0.84 (+0.45%) ▲|BAC50.69-0.39 (-0.76%) ▼|BKNG157.14-3.96 (-2.46%) ▼|BLK1,113.83-23.46 (-2.06%) ▼|BMY61.60-1.41 (-2.23%) ▼|BNY145.18-0.14 (-0.10%) ▼|BRK-B541.26-5.72 (-1.04%) ▼|C120.98-1.53 (-1.25%) ▼|CAT687.03-17.02 (-2.42%) ▼|CL93.96-3.44 (-3.53%) ▼|CMCSA22.79-0.06 (-0.24%) ▼|COF200.41-3.03 (-1.49%) ▼|COP151.55+5.92 (+4.06%) ▲|COST1,005.69-12.53 (-1.23%) ▼|CRM248.53-1.76 (-0.70%) ▼|CSCO106.27+1.38 (+1.31%) ▲|CVS93.49-0.99 (-1.05%) ▼|CVX232.73+6.05 (+2.67%) ▲|DE644.45+0.83 (+0.13%) ▲|DHR227.11-2.64 (-1.15%) ▼|DIS112.83-0.30 (-0.27%) ▼|DUK124.62-0.78 (-0.62%) ▼|EMR162.15+1.86 (+1.16%) ▲|FDX299.08-4.84 (-1.59%) ▼|GD350.40-0.39 (-0.11%) ▼|GE287.94-5.60 (-1.91%) ▼|GEV825.89-1.53 (-0.18%) ▼|GILD156.61-0.58 (-0.37%) ▼|GM75.84-1.38 (-1.78%) ▼|GOOG319.00-1.76 (-0.55%) ▼|GOOGL322.04-2.18 (-0.67%) ▼|GS882.67-8.63 (-0.97%) ▼|HD318.43-9.30 (-2.84%) ▼|HON221.41+3.10 (+1.42%) ▲|IBM252.93+0.82 (+0.33%) ▲|INTC86.84+1.35 (+1.57%) ▲|INTU346.15-8.75 (-2.47%) ▼|ISRG453.48+9.63 (+2.17%) ▲|JNJ263.03-4.59 (-1.71%) ▼|JPM332.14-4.41 (-1.31%) ▼|KO92.81-2.54 (-2.66%) ▼|LIN508.28-2.08 (-0.41%) ▼|LLY1,264.74-41.96 (-3.21%) ▼|LMT606.54+16.63 (+2.82%) ▲|LOW198.74-5.63 (-2.75%) ▼|LRCX230.80+0.65 (+0.28%) ▲|MA622.06-11.15 (-1.76%) ▼|MCD247.61-5.02 (-1.99%) ▼|MDLZ63.54-1.65 (-2.53%) ▼|MDT95.87-0.72 (-0.75%) ▼|META644.58-4.28 (-0.66%) ▼|MMM173.96-1.61 (-0.91%) ▼|MO74.46-1.61 (-2.12%) ▼|MRK145.00-2.24 (-1.52%) ▼|MS180.85-3.12 (-1.70%) ▼|MSFT524.59+3.51 (+0.67%) ▲|MU883.15+26.66 (+3.11%) ▲|NEE81.71-0.19 (-0.23%) ▼|NFLX66.12-0.93 (-1.39%) ▼|NKE37.48-0.85 (-2.21%) ▼|NOW158.45+1.45 (+0.92%) ▲|NVDA211.67-0.54 (-0.25%) ▼|ORCL127.74+2.20 (+1.75%) ▲|PEP135.50-3.34 (-2.40%) ▼|PFE30.04-0.38 (-1.25%) ▼|PG161.31-3.19 (-1.94%) ▼|PLTR196.12-0.08 (-0.04%) ▼|PM199.53-2.21 (-1.10%) ▼|QCOM174.94+2.11 (+1.22%) ▲|RTX191.65-3.07 (-1.57%) ▼|SBUX100.70-1.21 (-1.19%) ▼|SCHW90.45-0.99 (-1.08%) ▼|SO92.91-0.92 (-0.98%) ▼|SPG210.98-1.06 (-0.50%) ▼|T21.23-1.52 (-6.66%) ▼|TMO670.40-6.14 (-0.91%) ▼|TMUS148.89-9.90 (-6.23%) ▼|TSLA372.06-2.52 (-0.67%) ▼|TXN284.60+5.10 (+1.82%) ▲|UBER67.21-1.87 (-2.70%) ▼|UNH417.92-7.07 (-1.66%) ▼|UNP294.02-4.07 (-1.37%) ▼|UPS101.29-0.23 (-0.23%) ▼|USB59.61-0.41 (-0.68%) ▼|V409.13-5.21 (-1.26%) ▼|VZ44.46-0.74 (-1.64%) ▼|WFC82.36-0.66 (-0.79%) ▼|WMT119.41-1.71 (-1.41%) ▼|XOM182.62+4.39 (+2.46%) ▲|AAPL346.47-1.76 (-0.50%) ▼|ABBV286.27+1.08 (+0.38%) ▲|ABT103.39+0.88 (+0.85%) ▲|ACN246.85-11.89 (-4.60%) ▼|ADBE265.46-5.09 (-1.88%) ▼|AMAT379.68+4.10 (+1.09%) ▲|AMD517.55+9.62 (+1.89%) ▲|AMGN440.79-6.50 (-1.45%) ▼|AMT188.31+6.74 (+3.71%) ▲|AMZN248.72-1.66 (-0.66%) ▼|AVGO324.44+1.20 (+0.37%) ▲|AXP313.19-11.99 (-3.69%) ▼|BA188.39+0.84 (+0.45%) ▲|BAC50.69-0.39 (-0.76%) ▼|BKNG157.14-3.96 (-2.46%) ▼|BLK1,113.83-23.46 (-2.06%) ▼|BMY61.60-1.41 (-2.23%) ▼|BNY145.18-0.14 (-0.10%) ▼|BRK-B541.26-5.72 (-1.04%) ▼|C120.98-1.53 (-1.25%) ▼|CAT687.03-17.02 (-2.42%) ▼|CL93.96-3.44 (-3.53%) ▼|CMCSA22.79-0.06 (-0.24%) ▼|COF200.41-3.03 (-1.49%) ▼|COP151.55+5.92 (+4.06%) ▲|COST1,005.69-12.53 (-1.23%) ▼|CRM248.53-1.76 (-0.70%) ▼|CSCO106.27+1.38 (+1.31%) ▲|CVS93.49-0.99 (-1.05%) ▼|CVX232.73+6.05 (+2.67%) ▲|DE644.45+0.83 (+0.13%) ▲|DHR227.11-2.64 (-1.15%) ▼|DIS112.83-0.30 (-0.27%) ▼|DUK124.62-0.78 (-0.62%) ▼|EMR162.15+1.86 (+1.16%) ▲|FDX299.08-4.84 (-1.59%) ▼|GD350.40-0.39 (-0.11%) ▼|GE287.94-5.60 (-1.91%) ▼|GEV825.89-1.53 (-0.18%) ▼|GILD156.61-0.58 (-0.37%) ▼|GM75.84-1.38 (-1.78%) ▼|GOOG319.00-1.76 (-0.55%) ▼|GOOGL322.04-2.18 (-0.67%) ▼|GS882.67-8.63 (-0.97%) ▼|HD318.43-9.30 (-2.84%) ▼|HON221.41+3.10 (+1.42%) ▲|IBM252.93+0.82 (+0.33%) ▲|INTC86.84+1.35 (+1.57%) ▲|INTU346.15-8.75 (-2.47%) ▼|ISRG453.48+9.63 (+2.17%) ▲|JNJ263.03-4.59 (-1.71%) ▼|JPM332.14-4.41 (-1.31%) ▼|KO92.81-2.54 (-2.66%) ▼|LIN508.28-2.08 (-0.41%) ▼|LLY1,264.74-41.96 (-3.21%) ▼|LMT606.54+16.63 (+2.82%) ▲|LOW198.74-5.63 (-2.75%) ▼|LRCX230.80+0.65 (+0.28%) ▲|MA622.06-11.15 (-1.76%) ▼|MCD247.61-5.02 (-1.99%) ▼|MDLZ63.54-1.65 (-2.53%) ▼|MDT95.87-0.72 (-0.75%) ▼|META644.58-4.28 (-0.66%) ▼|MMM173.96-1.61 (-0.91%) ▼|MO74.46-1.61 (-2.12%) ▼|MRK145.00-2.24 (-1.52%) ▼|MS180.85-3.12 (-1.70%) ▼|MSFT524.59+3.51 (+0.67%) ▲|MU883.15+26.66 (+3.11%) ▲|NEE81.71-0.19 (-0.23%) ▼|NFLX66.12-0.93 (-1.39%) ▼|NKE37.48-0.85 (-2.21%) ▼|NOW158.45+1.45 (+0.92%) ▲|NVDA211.67-0.54 (-0.25%) ▼|ORCL127.74+2.20 (+1.75%) ▲|PEP135.50-3.34 (-2.40%) ▼|PFE30.04-0.38 (-1.25%) ▼|PG161.31-3.19 (-1.94%) ▼|PLTR196.12-0.08 (-0.04%) ▼|PM199.53-2.21 (-1.10%) ▼|QCOM174.94+2.11 (+1.22%) ▲|RTX191.65-3.07 (-1.57%) ▼|SBUX100.70-1.21 (-1.19%) ▼|SCHW90.45-0.99 (-1.08%) ▼|SO92.91-0.92 (-0.98%) ▼|SPG210.98-1.06 (-0.50%) ▼|T21.23-1.52 (-6.66%) ▼|TMO670.40-6.14 (-0.91%) ▼|TMUS148.89-9.90 (-6.23%) ▼|TSLA372.06-2.52 (-0.67%) ▼|TXN284.60+5.10 (+1.82%) ▲|UBER67.21-1.87 (-2.70%) ▼|UNH417.92-7.07 (-1.66%) ▼|UNP294.02-4.07 (-1.37%) ▼|UPS101.29-0.23 (-0.23%) ▼|USB59.61-0.41 (-0.68%) ▼|V409.13-5.21 (-1.26%) ▼|VZ44.46-0.74 (-1.64%) ▼|WFC82.36-0.66 (-0.79%) ▼|WMT119.41-1.71 (-1.41%) ▼|XOM182.62+4.39 (+2.46%) ▲|
15.7 C
New York
Friday, October 23, 2026

Tag: drug

newsFORsourcecompanycontentinformation1releasesmarket

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2A phase II...

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2A phase II...

EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer

OSLO, Norway, June 24, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial.

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vestis, PepGen, and Tempus and Encourages Investors to Contact...

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Vestis Corporation (NYSE:VSTS), PepGen, Inc. (NASDAQ: PEPG), and Tempus AI, Inc. (NASDAQ: TEM). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Bragar Eagel & Squire, P.C. Is Investigating Arvinas, Semler, and Abacus and Encourages Investors to Contact the Firm

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Arvinas, Inc. (NASDAQ:ARVN), Semler Scientific Inc. (NASDAQ:SMLR), and Abacus Global Management, Inc. (NASDAQ:ABL). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors...

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reckitt Benckiser Group plc (OTC:RBGLY), UroGen Pharma Ltd. (NASDAQ:URGN), Red Cat Holdings, Inc. (NASDAQ: RCAT) and Fortrea Holdings Inc. (NASDAQ:FTRE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

FDA’s Accelerated Drug Review Plan Praised by Former Senior Trump Health Official

Brett P. Giroir M.D., Former Acting FDA Commissioner and Assistant Secretary for Health, Says New Commissioner's National Priority Voucher Program (CNPV) Can Help Speed...

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

HUNTSVILLE, AL, June 23, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, is pleased to announce that Chief Executive Officer Steve Ledger will present at an upcoming FORCE Family Office investor webinar titled "New Drug Optimization Platform to Transform Parkinson’s Care.” The Event is scheduled to take place on Thursday, June 26, 2025, at 12:00 p.m. ET / 9:00 a.m. PT.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDrug

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers